for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ReNeuron Group Plc

RQE.L

Latest Trade

85.00GBp

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

69.13

 - 

174.29

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
85.00
Open
--
Volume
--
3M AVG Volume
1.85
Today's High
--
Today's Low
--
52 Week High
174.29
52 Week Low
69.13
Shares Out (MIL)
35.42
Market Cap (MIL)
29.22
Forward P/E
-2.59
Dividend (Yield %)
--

Next Event

ReNeuron Group PLC Annual Shareholders Meeting

Latest Developments

More

Reneuron Group Posts HY Loss Of £7.1 Mln

Reneuron Group Says Tim Corn Will Become Chairman Of Board

Reneuron Group Signs Research Evaluation Agreement With A Major U.S. Biotechnology Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ReNeuron Group Plc

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.

Industry

Biotechnology & Drugs

Contact Info

Pencoed Business Park

CF35 5HY

United Kingdom

+44.20.38198400

http://www.reneuron.com/

Executive Leadership

Timothy Henry Corn

Independent Non-Executive Chairman of the Board

Olav Hellebo

Chief Executive Officer, Executive Director

Michael Elliott Hunt

Chief Financial Officer, Executive Director, Company Secretary

Shaun Stapleton

Vice President Regulatory Affairs and Pharmacovigilance

Richard L. Beckman

Chief Medical Officer

Key Stats

Revenue (MM, GBP)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (GBp)

2018

-52.808

2019

-42.853

2020

-34.036

2021(E)

-33.223
Price To Earnings (TTM)
--
Price To Sales (TTM)
384.47
Price To Book (MRQ)
4.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.98
LT Debt To Equity (MRQ)
9.58
Return on Investment (TTM)
-103.30
Return on Equity (TTM)
-66.97

Latest News

Latest News

BRIEF-Reneuron Group Signs Research Evaluation Agreement With A Major U.S. Biotechnology Co

* RENEURON GROUP PLC - SIGNED A NEW RESEARCH EVALUATION AGREEMENT WITH A MAJOR US BIOTECHNOLOGY CO Source text for Eikon: Further company coverage:

BRIEF-Reneuron Group Gets FDA, MHRA Nod For Expanded Phase 2A Study In RP Patients

* RENEURON GROUP PLC - REGULATORY APPROVALS AND PROGRAMME UPDATE

BRIEF-Reneuron Says Ctx Cell Line Shows Further Potential

* RENEURON GROUP PLC - CTX CELL LINE SHOWS FURTHER POTENTIAL

BRIEF-Reneuron Signs Agreement With Unnamed Pharma Company

* RENEURON GROUP - SIGNED AGREEMENT WITH UNNAMED MAJOR PHARMA CO TO EXPLORE POTENTIAL USE OF CO'S PROPRIETARY EXOSOMES TO DELIVER NOVEL THERAPEUTICS. Source text for Eikon: Further company coverage:

BRIEF-ReNeuron Says Priority Internal Research Projects Are Continuing To Progress To Current Timelines

* RENEURON GROUP PLC - PRIORITY INTERNAL RESEARCH PROJECTS ARE CONTINUING TO PROGRESS TO CURRENT TIMELINES

BRIEF-Reneuron Initiates Research Programme Focused On Potential Utility Of Proprietary Exosomes

* RENEURON GROUP - INITIATED A RESEARCH PROGRAMME FOCUSED ON POTENTIAL UTILITY OF ITS PROPRIETARY EXOSOMES AS A DELIVERY VEHICLE FOR VIRAL VACCINES

BRIEF-ReNeuron Announces Positive Long-Term Data In Retinal Clinical Trial

* RENEURON GROUP PLC - POSITIVE LONG-TERM DATA IN RETINAL CLINICAL TRIAL

BRIEF-Reneuron Group Says Initial Cancer Clinical Trial Application Planned For 2019

* RENEURON GROUP PLC - PHASE I/II STUDY TO BE EXPANDED TO TARGET PATIENTS WITH LESS IMPAIRED VISION AHEAD OF FUTURE PHASE IIB STUDY

BRIEF-Reneuron Group Says ‍Phase II stroke Data Presented At AHA Conference

* POSITIVE LONG-TERM DATA FROM PHASE II CLINICAL TRIAL OF ITS CTX CELL THERAPY CANDIDATE FOR STROKE DISABILITY WAS ACCEPTED FOR PRESENTATION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up